Urokinase is a thrombolytic drug commonly known as a clot-busting drug. Urokinase is a type of plasminogen activator, which is a serine protease present in humans and animals. It helps the body to produce a substance that dissolves unwanted blood clots, especially in the lungs. It is administrated slowly into the vein via intravenous route over 12 hours by using a continuous infusion pump.
Urokinase increases the risk of bleeding, which can be severe or life-threatening. Urokinase was previously used globally in healthcare markets, but now it is a monopoly. Presently only one thrombolytic drug known as tissue plasminogen activator or TPA is available for dissolving blood clots in clinics and hospitals.
COVID-19 Impact analysis
In December 2019, the World Health Organization announced the COVID-19 virus outbreak as a public health emergency. The disease has spread to over 100 countries and affected huge losses of lives around the globe. Particularly the global manufacturing, pharmaceutical, tourism, and financial markets have been hit hard. The outbreak of the pandemic has added risk factors to the already weak growth of the world economy. The descending pressure on the world economy that once showed signs of improvement in the previous period has improved again.
The negative global impacts of the COVID-19 are already there, substantially affecting the global Urokinase for injection market in the coming years, and this factor is expected to have a significantly negative impact on the revenue growth of this industry.
Top Impacting Factors
- Increase in cases of cardiovascular diseases, surge in geriatric populations, rise in demand for minimally invasive procedures are factors that drive the growth of the Urokinase for injection market.
- Rise in prevalence of pulmonary embolism globally has boosted demand for blood clot-busting agents such as urokinase, which, in turn, propels the market growth.
- In addition, increase in healthcare expenditure, availability of skilled professionals, collaborations & partnerships between key players to facilitate drug development, rise in R&D activities to improve quality of drugs, and launch of the novel developed drug in market boost the market growth for urokinase injection.
- Urokinase is contraindicated in hypertension patients and also in cancer patients, as urokinase elevates plasminogen activation systems, which causes tissue invasion, and, in turn, leads to metastasis and causes cancer growth. These factors restrain the growth of the global urokinase market.
Market Trends
New product launches to flourish the market
In 2018, Microbix Biosystem Inc., a biologics product manufacturer, entered into an agreement with Toreya Partners LLC for re-launch of kinlytics (urokinase) a clot busting drug in the U.S. market.
In 2019 Syner Medica LTD received approval for marketing of Syner-kinase (urokinase) in the UK by European Medical Agency.
In March 2018, Microbix Biosystems Inc., a Canadian biotechnology company commercializing novel technologies, and Cadila Healthcare Ltd. (Zydus Cadila) said that they have signed a Letter of Intent (LoI) to market the thrombolytic drug urokinase in the North American market.
Surge in usage due to cardiovascular disorders
Cardiovascular diseases are gradually becoming the leading cause of morbidity and mortality globally. Cardiovascular disorders are on rise worldwide due to raised blood lipids, obesity, alcohol abuse, hypertension, diabetes, and age-related risks. The use of classical anticoagulant and antiplatelet therapies combined with surgical intervention helped to clear blood clots during the inceptive years. However, the discovery of streptokinase and urokinase steered the way of using these enzymes as thrombolytic agents to degrade the fibrin network with an issue of systemic hemorrhage.
Rise in prevalence of pulmonary embolism globally has boosted the demand for blood clot-busting agents such as urokinase. For instance, according to the National Library of Health in 2018, pulmonary embolism has a high prevalence globally with 10 million cases per year. Moreover, usage of urokinase in the treatment of cardiovascular disease is driving demand for blood clot-busting agents such as urokinase injection.
Key Benefits of the Report
- This study presents the analytical depiction of the urokinase for injection market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the urokinase for injection market share.
- The current market is quantitatively analyzed to highlight the Urokinase for injection market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Urokinase for Injection Report
- Who are the leading market players active in the urokinase for injection market?
- What current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What is "urokinase for injection"?
- What is "urokinase for injection" market prediction in the future?
- Who are the leading global players in the "urokinase for injection" market?
- What are the current trends and predicted trends?
Urokinase for Injection Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By End User |
|
 By Region |
|
 Key Market Players | Jiangsu Aidea Pharmaceutical, NDPharm,, Jiangxi Haoran Bio-Pharma,, Wanhua Biochem, |
Loading Table Of Content...
